stoxline Quote Chart Rank Option Currency Glossary
Ocuphire Pharma, Inc. (OCUP)
2.7  0 (0%)    11-29 10:33
Open: 2.71
High: 2.7399
Volume: 19,365
Pre. Close: 2.7
Low: 2.7
Market Cap: 61(M)
Technical analysis
2023-11-29 10:18:41 AM
Short term     
Mid term     
Targets 6-month :  3.53 1-year :  3.81
Resists First :  3.02 Second :  3.26
Pivot price 2.89
Supports First :  2.63 Second :  2.18
MAs MA(5) :  2.76 MA(20) :  2.9
MA(100) :  3.59 MA(250) :  3.83
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  16.6 D(3) :  19.3
RSI RSI(14): 39.3
52-week High :  6.59 Low :  2.48
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ OCUP ] has closed above bottom band by 18.2%. Bollinger Bands are 1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.8 - 2.82 2.82 - 2.83
Low: 2.59 - 2.6 2.6 - 2.62
Close: 2.67 - 2.7 2.7 - 2.73
Company Description

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

Headline News

Tue, 28 Nov 2023
Ocuphire Pharma Reports Inducement Grant under Nasdaq Listing ... -

Tue, 28 Nov 2023
Open-Angle Glaucoma Therapeutics Market size to grow by USD 2.36 billion from 2022 to 2027, North America to account for 51% of market growth - Technavio - Yahoo Finance

Mon, 27 Nov 2023
Oral APX3330 Receives FDA Nod for Phase 3 Endpoint in Diabetic ... - MD Magazine

Mon, 27 Nov 2023
Appointments and advancements for Nov. 27, 2023 - BioWorld Online

Mon, 27 Nov 2023
Ocuphire Pharma Names Joseph Schachle COO - Nasdaq

Mon, 27 Nov 2023
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 23 (M)
Shares Float 22 (M)
Held by Insiders 4.1 (%)
Held by Institutions 18.9 (%)
Shares Short 1,740 (K)
Shares Short P.Month 1,810 (K)
Stock Financials
EPS 1.44
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.22
Profit Margin 50.2 %
Operating Margin 53.5 %
Return on Assets (ttm) 52.8 %
Return on Equity (ttm) 92.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 2.52
EBITDA (p.s.) 1.28
Qtrly Earnings Growth 0 %
Operating Cash Flow 23 (M)
Levered Free Cash Flow 11 (M)
Stock Valuations
PE Ratio 1.88
PEG Ratio 0
Price to Book value 1.22
Price to Sales 1.07
Price to Cash Flow 2.66
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android